Just Toxicity, or Toxicity As a Biomarker of Efficacy of Ramucirumab in Breast Cancer?

J Clin Oncol. 2015 Aug 20;33(24):2712. doi: 10.1200/JCO.2015.60.8992. Epub 2015 Jul 20.

Authors

Hyo Jin Lee¹, Hyewon Ryu², Yoon Seok Choi², Ik-Chan Song², Hwan-Jung Yun², Deog-Yeon Jo², Samyong Kim²

Affiliations

¹ School of Medicine, Chungnam National University and Chungnam National University Hospital; and Cancer Research Institute, Chungnam National University, Daejeon, Republic of Korea cymed@cnu.ac.kr.
² School of Medicine, Chungnam National University and Chungnam National University Hospital; and Cancer Research Institute, Chungnam National University, Daejeon, Republic of Korea.

PMID: 26195714
DOI: 10.1200/JCO.2015.60.8992

No abstract available

Publication types

Letter
Comment

MeSH terms

Antibodies, Monoclonal / administration & dosage*
Antibodies, Monoclonal / adverse effects*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Breast Neoplasms / drug therapy*
Breast Neoplasms / pathology*
Female
Humans
Neoplasm Recurrence, Local / drug therapy*

Substances

Antibodies, Monoclonal